Focus on Computer Resources | Free Article
Warren Kibbe, Juli Klemm and John Quackenbush
Cancer Res November 1 2017 77 (21) e1-e2; DOI:10.1158/0008-5472.CAN-17-2212
These findings highlight the utility of integrating spontaneous dog models of cancer in preclinical trials to evaluate targeted therapies.
These mechanistic findings reveal critical tyrosine kinase andDNA methylation pathways in liposarcoma, some with immediate implications for therapeutic exploration.
These findings suggest that efforts to limit transsulfuration pathways that upregulate H2S production may have preventive benefits in limiting colorectal cancer.
This study reveals protein citrullination, a unique type of protein modification, as a novel pathogenic contributor to advanced prostate cancer, with immediate implications for its potential treatment given the opportunity to reposition modalities currently in clinical development for arthritis therapy.
These findings indicate that the transcription factor YAP, a classic oncogene in lung adenocarcinoma, acts as a tumor suppressor in lung squamous cell carcinoma.
These results establish the long noncoding RNA MetaLnc9 as a driver of metastasis and a candidate therapeutic target for treating advanced NSCLC.
These striking findings show that the pyruvate dehydrogenase complex, which biochemically links glycolysis to the TCA cycle, can be completely eliminated without significantly affecting normal or neoplastic proliferation.
These results illuminate the mechanism through which glioma-associated mesenchymal stem cells enhance the aggressiveness of glioblastoma.
These findings establish that KIT exerts a negative modifier role in melanoma by attenuating BRAFV600E activity.
These results suggest a secreted tumor suppressor has the potential to be developed as a novel prognostic biomarker and novel therapeutic target in liver cancer.
Conditional transgenic mouse models establish a new role for an ECM regulator in metastatic invasion that is independent of its canonical function in ECM remodeling.
These findings demonstrate how in vitro culture selections applied to genetically heterogenous tumors that occur rarely may help identify focal mutations that are pharmaceutically actionable in rare cancers, as in the case here for ependymoma, a rare cancer of the central nervous system.
Restoring β-catenin activity in Wnt5Ahigh melanoma cells sensitizes them to inhibition by the lysosomotropic agent Lys05, a finding of significance as studies to inhibit autophagy move into the clinic.
These findings reveal a critical regulator of oncogenesis and metastasis in esophageal squamous cell carcinoma and highlight its potential as a biomarker and therapeutic target.
Breast cancer stem-like cells that can recapitulate triple-negative breast tumors were used in this study to help validate therapeutic targets such as the epigenetic regulator KDM4.
These findings show how blocking the lactate transporter MCT1 rewires metabolism to enable tumor cell survival under therapeutic challenge.
These findings define a key lipid raft-bound plasma membrane scaffolding protein as a predictive biomarker for the response to albumin-conjugated cancer drugs, such as the widely used antimitotic agent Abraxane.
These findings describe a strategy to improve natural killer cells as a cellular immunotherapy for cancer by engineering them to express a fusion protein that tethers interleukin-2 to its receptor IL2Rβ.
These findings suggest TIMP1 as an appealing therapeutic target in pancreatic cancer, which continues to defy effective treatment.
An enzyme that controls membrane composition and dynamics in cancer cells is a potential therapeutic target for immunomodulatory therapy in lung adenocarcinoma.
This study identifies fundamental mechanisms of metastasis through the use of novel models of this process.
This potentially seminal study suggests a nodal role for CD137-CD137L immune signaling in the coordinate control of tumor immunosurveillance, spotlighting CD137L as an attractive intervention point to enhance cancer immunotherapy.
These seminal findings show that adequate immune surveillance depends vitally on the generation of cancer-specific antibodies.
These findings introduce a label-free imaging technology capable of performing live, longitudinal analysis of 3D tumor spheroids for high-throughput screening of anticancer drugs.
Photodynamic therapy after chemotherapy is a promising cancer treatment strategy, with macrophage-specific molecular imaging an important potential aid in the rational design of combination therapies.
A retrospect cohort of 14,766 women with stage I/II breast cancer suggests that metformin may be a preferred treatment for diabetes among women with breast cancer.